The Top Biotech Stocks to Watch Following ASH 2019
The annual American Society of Hematology (ASH) conference has historically been fertile ground for revolutionary advances in the treatment of blood disorders and cancers. This year was no exception. Among the thousands of presentations at the conference, a number of groundbreaking advances were reported, including impressive results in multiple myeloma, beta thalassemia, acute myeloid leukemia, hemophilia, and chronic lymphocytic leukemia. Will these indications be transformed by new treatment options? In this episode of The Motley Fool's Industry Focus: Healthcare, Shannon Jones is joined by Todd Campbell to break down ASH 2019's most important stories, including:
Listen in to learn more about the top stocks that could benefit from these developments, including Johnson & Johnson (NYSE: JNJ), Bristol-Myers Squibb (NYSE: BMY), bluebird bio (NASDAQ: BLUE), Forty-Seven (NASDAQ: FTSV), and uniQure (NASDAQ: QURE).
To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video.
Source Fool.com
